Drug Search Results
More Filters [+]

DWP-213388

Alternative Names: DWP-213388, DWP213388, DWP 213388, DWJ-213, DWJ213
Latest Update: 2024-11-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: IL2 Inhibitor,Btk Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DWP-213388

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Phase 0: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DW_DWP213388101

P1

Withdrawn

Healthy Volunteers

2024-02-20

Recent News Events